Beam Therapeutics IncNASDAQ:BEAM
- LAST PRICE27.3700
- TODAY'S CHANGE (%)0.1700 (0.6250%)
- Bid / Lots27.3700/ 1
- Ask / Lots28.2300/ 1
- Open / Previous Close27.4100 / 27.2000
- Day Range
- 52 Week Range
- Volume568,879
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BEAM |
|---|---|---|
| 09:32 ET | 11691 | 27.76 |
| 09:33 ET | 1500 | 27.55 |
| 09:35 ET | 950 | 27.4 |
| 09:37 ET | 2906 | 27.2 |
| 09:39 ET | 15116 | 27.35 |
| 09:42 ET | 3057 | 27.13 |
| 09:44 ET | 5019 | 27.25 |
| 09:46 ET | 1241 | 27.415 |
| 09:48 ET | 7927 | 27.6 |
| 09:50 ET | 2806 | 27.775 |
| 09:51 ET | 3442 | 27.71 |
| 09:53 ET | 3513 | 27.48 |
| 09:57 ET | 1100 | 27.55 |
| 10:00 ET | 2050 | 27.3902 |
| 10:02 ET | 3071 | 27.54 |
| 10:04 ET | 1606 | 27.59 |
| 10:06 ET | 4464 | 27.93 |
| 10:08 ET | 1542 | 27.89 |
| 10:09 ET | 7753 | 27.82 |
| 10:11 ET | 2550 | 27.93 |
| 10:13 ET | 4430 | 28.1 |
| 10:15 ET | 2339 | 27.97 |
| 10:18 ET | 3508 | 27.67 |
| 10:20 ET | 1848 | 27.75 |
| 10:22 ET | 1300 | 27.85 |
| 10:24 ET | 4774 | 27.81 |
| 10:26 ET | 2050 | 27.875 |
| 10:27 ET | 700 | 27.73 |
| 10:29 ET | 700 | 27.73 |
| 10:31 ET | 2093 | 27.78 |
| 10:33 ET | 1512 | 27.83 |
| 10:36 ET | 1088 | 27.825 |
| 10:38 ET | 2886 | 27.79 |
| 10:40 ET | 1650 | 27.68 |
| 10:42 ET | 1188 | 27.715 |
| 10:44 ET | 300 | 27.69 |
| 10:45 ET | 400 | 27.74 |
| 10:47 ET | 1138 | 27.8 |
| 10:49 ET | 700 | 27.86 |
| 10:51 ET | 830 | 27.93 |
| 10:54 ET | 12880 | 27.94 |
| 10:56 ET | 2324 | 27.965 |
| 10:58 ET | 700 | 27.95 |
| 11:00 ET | 2130 | 27.87 |
| 11:02 ET | 300 | 27.88 |
| 11:03 ET | 500 | 27.86 |
| 11:05 ET | 640 | 27.85 |
| 11:07 ET | 55183 | 27.77 |
| 11:09 ET | 2007 | 27.73 |
| 11:12 ET | 1100 | 27.755 |
| 11:14 ET | 2773 | 27.765 |
| 11:16 ET | 1997 | 27.74 |
| 11:18 ET | 3205 | 27.6499 |
| 11:20 ET | 1062 | 27.52 |
| 11:21 ET | 800 | 27.59 |
| 11:23 ET | 529 | 27.575 |
| 11:25 ET | 276 | 27.6232 |
| 11:27 ET | 700 | 27.62 |
| 11:30 ET | 200 | 27.6 |
| 11:32 ET | 121 | 27.6 |
| 11:34 ET | 1353 | 27.62 |
| 11:36 ET | 561 | 27.635 |
| 11:38 ET | 100 | 27.66 |
| 11:39 ET | 1822 | 27.67 |
| 11:41 ET | 637 | 27.66 |
| 11:43 ET | 555 | 27.67 |
| 11:45 ET | 703 | 27.66 |
| 11:48 ET | 957 | 27.625 |
| 11:50 ET | 600 | 27.62 |
| 11:52 ET | 600 | 27.665 |
| 11:54 ET | 1050 | 27.63 |
| 11:56 ET | 923 | 27.7 |
| 11:57 ET | 100 | 27.7 |
| 11:59 ET | 1260 | 27.68 |
| 12:01 ET | 200 | 27.665 |
| 12:03 ET | 743 | 27.56 |
| 12:06 ET | 1330 | 27.61 |
| 12:08 ET | 1033 | 27.635 |
| 12:10 ET | 974 | 27.65 |
| 12:12 ET | 1363 | 27.71 |
| 12:14 ET | 747 | 27.7 |
| 12:15 ET | 308 | 27.71 |
| 12:17 ET | 544 | 27.67 |
| 12:19 ET | 1629 | 27.605 |
| 12:21 ET | 2600 | 27.63 |
| 12:24 ET | 600 | 27.6325 |
| 12:26 ET | 1042 | 27.68 |
| 12:28 ET | 1573 | 27.64 |
| 12:30 ET | 1446 | 27.745 |
| 12:32 ET | 600 | 27.73 |
| 12:33 ET | 2579 | 27.7 |
| 12:35 ET | 900 | 27.72 |
| 12:37 ET | 2234 | 27.7 |
| 12:39 ET | 1548 | 27.725 |
| 12:42 ET | 1258 | 27.7 |
| 12:44 ET | 3115 | 27.67 |
| 12:46 ET | 2700 | 27.7 |
| 12:48 ET | 1438 | 27.665 |
| 12:50 ET | 3200 | 27.68 |
| 12:51 ET | 1598 | 27.595 |
| 12:53 ET | 4855 | 27.525 |
| 12:55 ET | 4669 | 27.4 |
| 12:57 ET | 9217 | 27.41 |
| 01:00 ET | 135359 | 27.37 |
Nov 12, 2024
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
DJ Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
DJ Beam Therapeutics Is Maintained at Sector Perform by RBC Capital, from 11:10AM ET on Wednesday Nov 06, 2024 by Dow Jones
11:10AM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Beam Therapeutics Raised to Outperform From Market Perform by Leerink Partners, from 7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Press Release: Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting, from 9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beam Therapeutics Inc | 2.1B | -15.9x | --- |
Genmab A/S | 14.2B | 21.3x | +22.71% |
Galapagos NV | 1.8B | -28.8x | --- |
Catalyst Pharmaceuticals Inc | 2.7B | 18.8x | --- |
BioCryst Pharmaceuticals Inc | 1.6B | -12.4x | --- |
Amicus Therapeutics Inc | 3.0B | -28.8x | --- |
Company Information
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Contact Information
- Headquarters
- 238 Main StreetCAMBRIDGE, MA, United States 02142
- Phone
- 857-327-8775
- Fax
- 302-655-5049
Executives
- President
- Giuseppe Ciaramella
- Chief Executive Officer, Principal Financial and Accounting Officer, Director
- John Evans
- Chief Medical Officer
- Amy Simon
- Chief Legal Officer and Secretary
- Christine Bellon
- Lead Independent Director
- Mark Fishman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
|---|---|
Revenue (TTM) | $349.6M |
Shares Outstanding | 82.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.90 |
EPS | $-1.72 |
Book Value | $12.02 |
P/E Ratio | -15.9x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -52.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
